An Experimental Study of In Vitro Transdermal Drug Delivery Assisted by Cryopneumatic Technology

Transdermal drug delivery (TDD) is a promising alternative to conventional drug delivery approaches, such as oral or injectable routes. In comparison, the primary benefits of TDD include [1]: 1) avoidance of first pass metabolism and other variables associated with the GI tract such as pH changes and gastric emptying time. 2) sustained and controlled delivery over a prolonged period of time. 3) reduction in side effects associated with systemic toxicity. 4) improved patient acceptance and compliance. 5) direct access to targeted or diseased site, e.g. treatment of skin disorders. 6) ease of dose termination in the event of any adverse reactions either systemic or local; 7) convenient and painless administration; 8) ease of use and reduction of overall health care treatment costs; 9) viable alternative in circumstances where oral dosing is not possible (in unconscious or nauseated patients).